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Abstract 
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various 
receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib 
received approval in 2006 and became a standard treatment option in the first-line 
treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority 
compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line 
treatment in several trials. Most of the combination trials with sunitinib with various agents 
have led to considerable toxicity without improving efficacy. Sunitinib alone causes 
significant side effects and has a distinct profile with diarrhoea, hypertension, skin effects 
hypothyroidism, fatigue and nausea of special interest. The recommended dose of sunitinib 
in mRCC is 50 mg orally daily for 4 weeks, followed by 2 weeks off treatment (4/2 schedule). 
An alternative 2 weeks on, 1 week off schedule (2/1 schedule) seems to be of similar 
efficacy and better tolerability and could be more widely used in the future. An intermittent 
treatment strategy with a stop in remission and re-induction after progression showed 
efficacy in smaller trials and is currently being evaluated in a phase III trial. Direct 
comparison of sunitinib with pazopanib in first-line treatment showed a similar efficacy for 
both TKIs with a distinct toxicity profile. Data from two phase II trials showed that sunitinib 
has also activity in non-clear cell cancer and is an option due to a lack of better alternatives. 
Currently, after immune checkpoint inhibitors have shown very promising results in the 
second-line treatment of RCC, they are being tested in a number of phase III trials in the 
first-line setting. The future will show the position of sunitinib in the first-line treatment of 
RCC in the era of the immune checkpoint inhibitors. 
  
Introduction 
Sunitinib (sunitinib malate, Sutent®, SU11248, Pfizer Inc.) is an oral multi-targeted tyrosine-
kinase inhibitor (TKI) of vascular endothelial growth factor (VEGF) receptors (VEGFRs), 
platelet-derived growth factor (PDGF) receptors (PDGFRs), stem cell factor receptor (KIT) 
and FMS-like tyrosine kinase-3 (FLT3) receptor, as well as macrophage colony-stimulating 
factor receptor (CSF-R) and glial cell-line derived neurotrophic factor receptor [Farrell et al. 
2003; Mendel et al. 2003; Abrams et al. 2003; Osusky et al. 2004; Patyna et al. 2008; Chow 
and Eckhardt, 2007]. 
In 2012, renal cell cancer (RCC) accounted for an estimated 388,000 new cases (2.4% of all 
malignancies) and an estimated 144,000 deaths (1.7% of all deaths caused by cancer) 
worldwide [Ferlay et al. 2015]. Clear cell RCC is the most common histological subtype with 
a proportion of approximately 80% of all RCCs [Moch et al. 2000; Leibovich et al. 2010] and 
commonly associated with an inactivation of the von Hippel-Lindau (VHL) tumour 
suppressor gene [Kaelin, 2007]. VHL inactivation leads to an up-regulation of VEGF, PDGF 
and other promoters of angiogenesis and cellular growth, proliferation and migration. VEGF 
is seen as the key mediator of angiogenesis, which is essential for cancer development and 
growth [Rini, 2009; Carmeliet, 2005]. VEGF overexpression and a high degree of 
vascularization is one of the features of RCC [Herbst et al. 1998; Jacobsen et al. 2004]. 
Therefore, drugs inhibiting the VEGF pathway, such as sunitinib, play an important role in 
the treatment of RCC. 
The aim of this review is to provide an overview of the role of sunitinib in the management 
of metastatic RCC (mRCC) and to describe current schedules and toxicity management 
strategies. We also briefly discuss the use of sunitinib in the context of other targeted 
therapies and the newer immunotherapy agents. 
 
Early trials 
RCC is largely refractory to cytotoxic agents [Medical Research Council Renal Cancer 
Collaborators, 1999; Motzer et al. 1996]. Before the era of VEGF-targeted therapy, systemic 
treatment for advanced RCC was mainly limited to cytokine therapy with interleukin-2 (IL-2) 
or interferon-alpha (IFN-α), both of which effected objective responses, but in a small 
proportion of patients these agents were also associated with significant toxicities 
[McDermott et al. 2005; Coppin et al. 2005; Medical Research Council Renal Cancer 
Collaborators, 1999]. 
Sunitinib initially demonstrated promising antitumour activity in a phase I trial in patients 
with acute myeloid leukaemia [Fiedler et al. 2004]. Following this, a phase I dose-escalation 
study in solid malignancies was published in which three out of four patients with RCC had a 
response [Faivre et al. 2006]. Sunitinib was given orally in a 4 weeks on, 2 weeks off 
schedule (4/2 schedule) in order to allow patients to recover from the potential bone 
marrow and adrenal toxicity that had been observed in animal models. 
Subsequently, two open-label single-arm multicentre phase II trials of sunitinib in patients 
with mRCC who had progressed on first-line cytokine treatment were published by Motzer 
and colleagues [Motzer et al. 2006a, 2006b]. 
In the first trial, 40% of the patients had a partial response, as assessed by the ‘Response 
Evaluation Criteria in Solid Tumours’, RECIST [Therasse et al. 2000], and in addition 27% 
achieved stable disease lasting ⩾3 months. The median time to progression (TTP) was 8.7 
months [Motzer et al. 2006a]. The second trial confirmed the antitumour efficacy of 
sunitinib. Partial responses were achieved in 34% of the patients and the median 
progression free survival (PFS) was 8.3 months [Motzer et al. 2006b]. A pooled analysis of 
these two phase II trials with a total of 168 patients showed an objective response rate 
(ORR) of 42%, a rate of stable disease of ⩾3 months of 24% and a median PFS of 8.2 months 
[Motzer et al. 2006b]. 
 
First-line trials 
After having shown remarkable efficacy in the first two phase II trials, sunitinib was 
compared with IFN-α at first-line in a randomized phase III landmark trial in patients with 
clear cell mRCC [Motzer et al. 2007, 2009a]. A total of 750 patients were enrolled and 
received either sunitinib (50 mg/day on a 4/2 week schedule) or IFN-α subcutaneously at a 
standard dose of 9 MU three times weekly. The primary endpoint of median PFS was 
significantly longer in the sunitinib arm (11 months) compared with the IFN-α arm (5 
months), corresponding to a hazard ratio (HR) of 0.42 [95% confidence interval (CI) 0.32–
0.54; p < 0.001]. Sunitinib also resulted in significantly higher ORRs than IFN-α (31% versus 
6%; p < 0.001). The toxicity assessment showed a significantly higher proportion of grade 3 
or 4 treatment-related fatigue in the IFN-α group (p < 0.05), whereas grade 3 or 4 diarrhoea, 
vomiting, hypertension and hand-foot syndrome were significantly more frequent in the 
sunitinib group (p < 0.05 for all comparisons). However, quality of life as assessed by the 
Functional Assessment of Cancer Therapy (FACT), general (FACT-G) and Kidney Symptom 
Index (FKSI) questionnaires [Cella et al. 1993, 2006] was significantly better in the sunitinib 
group [Motzer et al. 2007]. 
In an updated analysis, the median overall survival (OS) was significantly longer in the 
sunitinib group, 26.4 months compared with 21.8 months for the IFN-α group (HR = 0.818; 
95% CI 0.669–0.999; p = 0.049 by stratified log-rank test). However, in pre-stratified poor-
risk patients (Memorial Sloan-Kettering Cancer Centre criteria) [Motzer et al. 2002], the 
median PFS as well as the median OS did not significantly differ between the sunitinib group 
and the IFN-α group although the number of patients in the poor-risk group was small, at 
only 48 patients [Motzer et al. 2009a]. 
Data from the large expanded access programme (EAP) in a broad, more heterogeneous 
population of 4543 patients who received sunitinib as first-line treatment, or after 
progression on cytokine or anti-angiogenic treatment, showed an overall ORR of 16%, a 
median PFS of 9.4 months and an OS of 18.7 months. The median PFS for subgroups of 
special interest was 10.1 months for elderly patients (age ⩾65 years), 3.5 months for 
patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ⩾2, 6 
months for non-clear cell histology, and 5.3 months for patients with brain metastases. 
Thrombocytopenia (10%), fatigue (9%), asthenia (7%), neutropenia (7%) and hand-foot 
syndrome (7%) were the most common grade 3/4 treatment-related adverse events. This 
study confirmed that sunitinib is effective and well-tolerated with manageable toxicities in a 
unselected group of patients [Gore et al. 2015]. 
On the basis of these trials, sunitinib received regulatory approval by the United States Food 
and Drug Administration (US FDA) and full marketing authorization by the European 
Medicines Agency (EMA) in 2007. It is still recommended as a first-line treatment option for 
advanced or metastatic predominantly clear cell RCC for patients with good, intermediate 
and poor-risk disease [NCCN Panel Members, 2016a; Escudier et al. 2014a]. 
Table 1 gives an overview of the early and first-line trials of sunitinib. 
 
Second-line and further-line trials 
The use of cytokines as a first-line treatment has decreased considerably so the emphasis of 
this section will be on the data relating to the role of sunitinib following other VEGF-
targeted agents. 
Several retrospective studies investigated the sequential use of sunitinib after sorafenib, 
another multi-targeted TKI with an overlapping but not identical kinase inhibition profile 
[Wilhelm et al. 2004]. Sunitinib showed activity after sorafenib in these strategies 
[Eichelberg et al. 2008; Dudek et al. 2009; Sablin et al. 2009; Zimmermann et al. 2009; Porta 
et al. 2011a]. In another retrospective study, patients who progressed after first-line 
sunitinib and had received subsequent therapies were re-challenged with sunitinib at the 
time of further progression. Sunitinib showed activity (ORR 22% and median PFS 7.2 months 
upon re-challenge) without additional or increased toxicities [Zama et al. 2010]. In a 
prospective study 22 patients with mRCC and progression after sorafenib were treated with 
sunitinib. The median PFS on sunitinib was 21.5 weeks with a 1-year survival of 60% 
[Zimmermann et al. 2009]. The open-label phase III SWITCH trial evaluated the sequential 
administration of sorafenib followed by sunitinib (So-Su) versus sunitinib followed by 
sorafenib (Su-So) on progression or intolerable toxicity in patients with mRCC. The primary 
endpoint was PFS following the end of the sequence of therapy, sometimes known as PFS2. 
There was no statistically significant difference between the two treatment sequences, 
median PFS2 was 12.5 months for So-Su and 14.9 months for Su-So (p = 0.5 for superiority). 
Median PFS to first-line treatment was 5.9 months for sorafenib and 8.5 months for 
sunitinib (NS; p = 0.9 for superiority), while at second-line it was 2.8 months for sorafenib 
and 5.4 months for sunitinib (HR 0.55, p < 0.001 for superiority) [Eichelberg et al. 2015]. The 
results of these studies are suggestive of a degree of non-cross-resistance between sunitinib 
and sorafenib. 
Rini and colleagues published a phase II multicentre trial with sunitinib as second-line 
treatment following disease progression after bevacizumab-based first-line treatment. The 
primary endpoint, ORR was 23%. Median PFS was 30.4 weeks and the median OS was 47.1 
weeks. The study showed that sunitinib has substantial antitumour activity in patients 
progressing after bevacizumab-based therapy [Rini et al. 2008a]. 
Table 2 provides an overview of the second-line or further line trials of sunitinib. 
 
Combination trials 
A number of studies have investigated sunitinib in combination with different agents. 
The addition of IFN-α to sunitinib was assessed in a phase I dose-finding trial in treatment 
naïve patients with clear cell mRCC. All patients developed grade 3/4 treatment-related 
adverse events and partial responses were only achieved in 12% of patients [Motzer et al. 
2009b]. These data compared unfavourably with those from the pivotal phase III trial of 
sunitinib alone which demonstrated partial responses in 31% of the patients [Motzer et al. 
2007]. The combination of sunitinib with IFN-α was therefore not investigated further. 
The tolerability and efficacy of sunitinib in combination with bevacizumab was explored in a 
phase I trial in patients with progressive mRCC. The ORR was high (52%) but treatment 
resulted in frequent grade 3/4 toxicities such as hypertension (60% grade 3/4), proteinuria 
and thrombocytopenia as well as thrombotic microangiopathy. Furthermore, 48% of 
patients had to discontinue treatment due to toxicity [Feldman et al. 2009]. In an expanded 
cohort of five patients in another phase I trial of the combination of sunitinib and 
bevacizumab three out of five patients had laboratory evidence of thrombotic 
microangiopathy [Rini et al. 2010a]. The high rates of grade 3/4 toxicity including thrombotic 
microangiopathy precluded further investigation of this combination. 
The combination of sunitinib and everolimus (an oral inhibitor of mammalian target of 
rapamycin pathway, mTOR) in advanced RCC was tested in two phase I trials. Both trials 
reported a high incidence of grade 3/4 toxicity, and the second trial was closed prematurely 
for this reason [Molina et al. 2012b; Kanesvaran et al. 2015]. 
The combination of sunitinib with temsirolimus, an intravenously administered mTOR 
pathway inhibitor was tested in a phase I study in patients with advanced RCC. The trial was 
terminated early due to dose-limiting toxicity that was seen at low doses of both drugs and 
the conclusion of the study investigators was that this combination should not be taken 
forward [Patel et al. 2009]. 
A recently published phase II trial investigated the combination of sunitinib with trebananib, 
an intravenous recombinant-Fc fusion protein that neutralizes the receptor-ligand 
interaction between Tie2 and angiopoietin-1/2. Trebananib was administered at two 
different doses (cohort A at 10 mg/kg and cohort B at 15 mg/kg). The rate of grade 3/4 
adverse events was 58% (cohort A) and 59% (cohort B), respectively. The ORRs were 58% 
(cohort A) and 63% (cohort B) and the median PFS were 13.9 months and 16.3 months in 
cohort A and B, respectively. These results suggest a potential benefit for this combination, 
but it appears to be associated with significant toxicity [Atkins et al. 2015]. 
In a phase II trial, published in 2015, AGS-003, an autologous dendritic cell-based 
immunotherapy was tested in combination with sunitinib in patients with intermediate and 
poor-risk mRCC according to Memorial Sloan-Kettering Cancer Center (MSKCC) and Heng 
risk scores [Motzer et al. 2004; Heng et al. 2009]. The ORR was 43%, the median PFS was 
11.2 months and 43% of the patients had grade 3 toxicities [Amin et al. 2015]. Given the 
promising results of this trial, an international phase III randomized trial (ADAPT) is ongoing 
(phase III Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard 
Treatment of Advanced Renal Cell Carcinoma (RCC; ADAPT) [ClinicalTrials.gov identifier: 
NCT01582672]). 
Preliminary results from a phase I trial (Checkmate 016) of sunitinib or pazopanib and 
nivolumab (anti-PD1 AB) have been published and show evidence of activity for the 
combination (ORR 52% for nivolumab plus sunitinib and 45% for nivolumab plus pazopanib) 
with a manageable safety profile [Amin et al. 2014; ClinicalTrials.gov identifier: 
NCT01472081]. 
Table 3 gives an overview of the combination trials. 
 
Toxicity management 
Sunitinib is associated with a significant burden of side effects. Adverse events of any grade 
were reported in approximately 95% of the patients in the large global sunitinib EAP 
representing a ‘real world’ population, although the incidence of grade 3/4 adverse events 
was 46% in patients with ECOG PS ⩾2 and 56% with ECOG zero or one. The most frequent 
adverse events of any grade were diarrhoea (47%), fatigue (40%), nausea (36%) and 
decreased appetite (31%) [Gore et al. 2015]. 
Toxicities from this EAP and the first-line phase III trial are listed in Tables 4 and 5. 
 
Toxicities of special interest 
Hypertension 
The incidence of grade 3/4 hypertension was 6% in the EAP [Gore et al. 2015]. Hypertension 
is regarded to be a class effect of angiogenesis inhibitors that target VEGF signalling [Sica, 
2006; Willett et al. 2004; Yang et al. 2003; Ahmad and Eisen, 2004; Escudier et al. 2007a; 
Soria et al. 2009]. Patients receiving sunitinib should be advised to measure their blood 
pressure at home and once hypertension occurs, antihypertensive treatment should be 
initiated with standard antihypertensive drugs. As sunitinib is primarily metabolized by the 
cytochrome P-450 (CYP) isoenzyme system, namely CYP3A4, physicians should avoid known 
CYP3A4 inhibitors such as diltiazem or verapamil as there are no data available on the safety 
of their concomitant use with sunitinib to date [Houk et al. 2009]. 
Hypothyroidism 
Grade 3/4 hypothyroidism occurred in 4% of the patients on sunitinib [Gore et al. 2015]. In a 
smaller, more detailed study of 66 patients treated with sunitinib, 85% had at least one 
abnormal thyroid function test, consistent with hypothyroidism and 71% of all patients had 
signs or symptoms that were possibly related to hypothyroidism. The thyroid function 
abnormality was detected early within a median of two cycles (range 1–14). Overall, 26% of 
all patients needed a thyroid hormone replacement, which improved symptoms in 50% of 
the patients [Rini et al. 2007]. In another analysis of 42 patients, 62% developed abnormal 
serum thyroid stimulating hormone concentrations and 36% developed persistent, primary 
hypothyroidism. The risk for the development of hypothyroidism was increased with the 
duration of sunitinib therapy [Desai et al. 2006]. Measurement of the thyroid function 
should be performed at baseline and thereafter on a regular basis; most would recommend 
3-monthly. 
Cardiac toxicity 
A decrease in the left ventricular ejection fraction (LVEF) is the main cardiac toxicity of 
sunitinib. Grade 3 LVEF decline was reported in 3% with no grade 4 decline in the phase III 
first-line trial [Motzer et al. 2009]. Patients with cardiac risk factors such as recent history of 
myocardial infarction, unstable angina or symptomatic congestive heart failure (CHF) were 
excluded from the sunitinib trials. It is not known if patients with pre-existing cardiac risk 
factors are at a higher risk to develop drug-related LVEF decline. Nevertheless, these 
patients should be carefully monitored for clinical signs and symptoms of CHF while 
receiving sunitinib. They should have baseline and periodic evaluations of LVEF [Pfizer 
Canada Inc., 2014]. The frequency of monitoring depends on the severity of the baseline 
cardiac function and co-morbidities. In patients without cardiac risk factors, a baseline 
evaluation of ejection fraction should be considered. In the presence of clinical 
manifestations of CHF, discontinuation of sunitinib is recommended [Pfizer Canada Inc., 
2014]. 
Skin toxicity 
Skin toxicity typically occurs after 3–4 weeks of a treatment [Faivre et al. 2006]. Hand-foot 
syndrome (palmar-plantar erythrodysesthesia) is one of the most common skin side effects, 
with grade 3/4 events reported in 7% of patients in the EAP [Gore et al. 2015]. As no 
randomized trials exist to determine the best management strategy for hand-foot 
syndrome, recommendations from expert opinion are the best guide. Preventative 
measures include manicure and pedicure, wearing thick cotton gloves, and the avoidance of 
hot water, constrictive footwear and excessive friction. If a patient develops hand-foot 
syndrome, topical treatment with intensive moisturizing creams such as those containing 
urea or lanolin is recommended. If grade ⩾2 hand-foot syndrome occurs, a steroid-based 
cream should be added and a dose reduction or break of sunitinib should be considered 
[Lacouture et al. 2008; Kollmannsberger et al. 2007; Pfizer Canada Inc., 2014]. 
Diarrhoea 
The incidence of grade 3/4 diarrhoea was 5% in the EAP [Gore et al. 2015]. Grade 1/2 
diarrhoea can commonly be managed by oral hydration and oral antidiarrheal agents such 
as loperamide as needed. Sunitinib treatment should be interrupted for grade 3/4 diarrhoea 
until diarrhoea is grade 1 or less. Usually, the diarrhoea resolves fast in the 2-week break 
between sunitinib cycles [Kollmannsberger et al. 2007; Motzer et al. 2006b; Pfizer Canada 
Inc., 2014]. 
Fatigue 
Fatigue is one of the most common adverse events with sunitinib but also in cancer patients 
generally. Grade 3 fatigue which limits self-care activities of daily living [National Institute of 
Cancer, 2010] occurred in 9% of the patients in the EAP [Gore et al. 2015]. It is advisable to 
undertake an assessment to identify potentially treatable contributing factors of fatigue 
such as anaemia, hypothyroidism, depression, pain, nutritional deficits/imbalances or sleep 
disturbance. General strategies for management of fatigue include light physical activity 
such as walking, use of welcome distractions such as listening to music, limiting naps during 
the day to under 1 h to not interfere with night-time sleep quality, eating well, and drinking 
plenty of fluids. Pharmacological intervention with psychostimulants (methylphenidate) may 
improve fatigue in some patients [NCCN Panel Members, 2016b; Kollmannsberger et al. 
2007; Minton et al. 2010]. 
Nausea 
The emetogenic potential of sunitinib is low [Grunberg et al. 2011]. While nausea of any 
grade has been reported by 36% of the patients with sunitinib, grade 3/4 nausea has only 
been noted in 2% in the EAP. If nausea occurs, common antiemetics should be used. 
However one should be aware of the concomitant use of sunitinib with antidopaminergic 
agents as domperidone and 5HT3 antagonists such as ondansetron as they all have the 
potential to prolong the QTc interval [Kollmannsberger et al. 2007; Rossi and Giorgi, 2010; 
Brygger et al. 2014]. Practical guidelines for the management of nausea are published by the 
National Comprehensive Cancer Network (NCCN) and the European Society of Medical 
Oncology (ESMO) [NCCN Panel Members, 2016c; Roila et al. 2010]. 
For further information about management of sunitinib toxicity in RCC see the 
comprehensive review by Kollmannsberger and colleagues [Kollmannsberger et al. 2007]. 
Toxicity and outcome 
Several of the above toxicities are thought to serve as independent predictive biomarkers 
for the treatment efficacy of sunitinib. The occurrence of treatment-related hypertension 
has been shown to be an independent biomarker of sunitinib efficacy. A large retrospective 
analysis included pooled data from 544 sunitinib-treated mRCC patients in the three 
prospective clinical trials. Patients with sunitinib-induced hypertension had better outcomes 
than those without treatment-induced hypertension in terms of ORR (54.8% versus 8.7%; p 
< 0.001), median PFS (12.5 months versus 2.5 months; p < 0.001) and median OS (30.9 
months versus 7.2 months; p < 0.001) [Rini et al. 2011]. In another large retrospective 
analysis of five randomized trials, with a total of 770 patients treated with sunitinib, the 
occurrence of hypertension as well as neutropaenia under treatment was associated with a 
prolonged PFS and OS, independent of baseline prognostic factors [Donskov et al. 2015]. 
Two analyses have suggested a correlation between good outcome and the development of 
hypothyroidism while on sunitinib [Kust et al. 2014; Nearchou et al. 2015]. In a retrospective 
analysis of 41 patients with mRCC treated with sunitinib, the occurrence of symptomatic 
hypothyroidism was associated with longer median PFS (25.3 months versus 9.0 months; p = 
0.042) but without a difference in median OS [Kust et al. 2014]. However, meta-analysis 
found no statistical significant difference in the PFS between patients who developed 
hypothyroidism on sunitinib therapy and unaffected patients (HR 0.82; p = 0.22; six studies, 
250 patients). An OS benefit was observed in patients who developed hypothyroidism (HR 
0.52; p = 0.01; four studies, 147 patients), but this should be interpreted with caution, 
because the trials did not report data for subsequent treatment after sunitinib [Nearchou et 
al. 2015]. 
 
Effects of sunitinib on the immune system 
Sunitinib and other multi-targeted TKIs inhibit signalling pathways which are also relevant in 
the immune system. For example, the administration of sunitinib has shown to increase the 
plasma VEGF levels [Deprimo et al. 2007]. VEGF, on the other hand, is able to inhibit the 
ability of mature dendritic cells to stimulate allogeneic T-cells [Mimura et al. 2007; Porta et 
al. 2011b]. 
Several studies have shown that sunitinib may enhance antitumour activity of the immune 
system: 
In a mouse model study, treatment with sunitinib reduced the number of myeloid-derived 
suppressor cells (MDSCs) and T-regulatory cells and resulted in a reduction of immune 
suppressive cytokines and co-stimulatory molecules such as IL-10, and in an enhanced 
expression of Th1 cytokine IFN-gamma. Even more importantly, the expression of the 
negative co-stimulatory molecules CTLA4 and PD-1 in both CD4 and CD8 T-cells, and PDL-1 
expression on MDSCs and plasmacytoid dendritic cells was significantly reduced by sunitinib 
treatment [Ozao-Choy et al. 2009]. 
In an in vitro trial, treatment with sunitinib in mRCC patients was found to result in a 
significant reduction in MDSCs [Ko et al. 2009], which are usually increased in RCC patients 
and represent a mechanism by which tumours induce T-cell suppression [Kusmartsev et al. 
2008; Ozao-Choy et al. 2009]. This MDSC reduction was correlated with reversal of type-1 T-
cell suppression as well as a reversal of T-regulatory cells elevation [Ko et al. 2009]. 
Immune suppression which includes a shift from a type-1 to a type-2 T-cell cytokine 
response and an enhanced T-regulatory cell expression has been reported in patients with 
mRCC. It has been shown that both can be reversed by sunitinib [Finke et al. 2008]. 
A disturbed myeloid lineage development with impaired dendritic cell differentiation may 
contribute to tumour immune escape. After one cycle of sunitinib, dendritic cell rates 
recovered and the myeloid lineage distribution was normalized [van Cruijsen et al. 2008]. 
However, results from another study imply, that sunitinib may also have immune 
suppressive effects. Sunitinib inhibited the proliferation of primary human T-cells from 
normal healthy volunteers and also from RCC and other cancer patients. This inhibition was 
recoverable after drug withdrawal [Gu et al. 2010]. The current evidence suggests that 
sunitinib has a considerable impact on the immune system. Most of the studies, but not all, 
show that sunitinib has mainly immune stimulatory effects; however the picture is not that 
clear. A comprehensive review of immunological effects of multikinase inhibitors for RCC 
was published by Porta and colleagues [Porta et al. 2011b]. 
 
Sunitinib schedules 
Four weeks on, 2 weeks off versus 2 weeks on, 1 week off 
The standard schedule for sunitinib is 50 mg once daily for 4 weeks, followed by a rest of 2 
weeks (4/2 schedule) to recover from side effects [Motzer et al. 2009a]. 
In a pharmacokinetic analysis, data from one phase II study with a 4/2 schedule were 
analysed and showed, that the concentration of sunitinib and its active metabolite SU12662 
decreases to pre-dose levels in the 2 weeks off period, indicating a potential lack of drug 
exposure during which the tumour could potentially progress [Houk et al. 2009]. 
An alternative continuous daily dosing schedule of sunitinib 37.5 mg once daily was 
compared with the standard intermittent schedule (50 mg once daily, 4/2 schedule) in a 
randomized phase III trial (Renal EFFECT trial). The ORR, median OS and adverse events 
were not significantly different. However, there was a trend towards an inferior median TTP 
in the continuous schedule and a statistically significant superiority in a composite endpoint 
of death, progression and disease-related symptoms for the 4/2 schedule (HR 0.77, p = 
0.034) [Motzer et al. 2012]. On the basis of these results, the 4/2 schedule remains the 
standard sunitinib schedule. 
Several retrospective studies showed promising results for a 2 weeks on, 1 week off 
schedule (2/1 schedule) in terms of efficacy and toxicity [Neri et al. 2012; Kletas et al. 2013; 
Atkinson et al. 2014; Kondo et al. 2014; Najjar et al. 2014; Bracarda et al. 2015]. The 
prospective randomized phase II RESTORE trial evaluated the efficacy and safety of the 
sunitinib 2/1 schedule versus the standard 4/2 schedule in 74 patients with clear cell mRCC. 
The 2/1 schedule resulted in a higher 6-month failure-free survival (the primary endpoint, 
63% versus 44%) and median time to treatment failure (7.6 versus 6.0 months, HR = 0.57, p 
= 0.029) without compromising the efficacy in terms of ORR (47% versus 33%) and TTP (12.1 
months versus 10.1 months). In addition the 2/1 schedule was associated with lower toxicity 
in terms of neutropaenia (all grades 61% versus 37%, p = 0.037) and fatigue (all grades 83% 
versus 58%, p = 0.017) and time to first dose reduction (HR = 0.35, p = 0.014) [Lee et al. 
2015]. The major limitation of the trial was the small sample size, powered only to select the 
schedule with higher failure-free survival and not to detect differences in ORR, TTP, and OS. 
The above data suggest, that patients who experience intolerable toxicities on a 4/2 
schedule could switch to a 2/1 schedule, which would likely improve tolerability without 
compromising efficacy. 
Table 6 provides an overview of the trials that investigated the 2/1 schedule. 
 
Stopping treatment in remission and reintroduction of sunitinib after 
progressive disease 
Several smaller studies support the strategy of ‘drug holidays’ (i.e. sunitinib free intervals). A 
retrospective study with 11 patients reported the consequences of stopping sunitinib after a 
complete response, with or without surgical metastasectomy, had been achieved. At a 
median follow up of 8.5 months after sunitinib discontinuation, five patients had relapsed, 
with a median TTP of 6 months. However, reintroduction of sunitinib was effective in 
regaining disease control in all cases [Johannsen et al. 2009]. These results were confirmed 
in an updated analysis of 22 patients [Johannsen et al. 2011]. Preliminary results from a 
prospective phase II trial of intermittent sunitinib in previously untreated patients with 
mRCC were presented at the American Society of Clinical Oncology Annual Meeting, 2013. A 
total of 36 patients were initially treated for four cycles with sunitinib, and patients 
achieving a ⩾10% reduction in tumour burden had sunitinib withheld. Sunitinib was 
reintroduced for two cycles in those patients with an increase in tumour measurements of 
⩾10% and discontinued after ⩾10% tumour burden reduction. This intermittent dosing was 
administered until RECIST-defined disease progression occurred. The ORR was 53% and 
most patients exhibited a stable saw-tooth pattern of tumour burden reduction on sunitinib 
with tumour burden increasing when off sunitinib. Toxicity resolved completely during the 
off-treatment periods. The results suggest that intermittent dosing of sunitinib may be 
better tolerated than standard fixed schedules without compromising efficacy [Rini et al. 
2013]. Currently, a randomized multicentre phase III study is ongoing (STAR trial) that 
compares the conventional schedule of sunitinib 50 mg daily 4/2 weeks with a drug-free 
interval strategy, namely a treatment break after completion of at least four cycles and 
maximal radiological response until progressive disease (PD) and then a restart of sunitinib 
for a minimum of four cycles and maximal radiological response [Collinson et al. 2012]. 
Where does sunitinib fit in first-line treatment? 
Sunitinib was compared in two trials with pazopanib, another approved and recommended 
TKI for first-line treatment for clear cell mRCC (Category 1 in NCCN guidelines and IA Level of 
recommendation in ESMO guidelines) [NCCN Panel Members, 2016a; Escudier et al. 2014a]. 
A randomized non-inferiority phase III trial (COMPARZ) involving 1100 patients compared 
pazopanib with sunitinib for the first-line treatment in clear cell mRCC. The two arms 
showed similar efficacy but a different safety profile. The study showed non-inferiority 
(predefined non-inferiority upper bound of the 95% CI < 1.25) for pazopanib for the primary 
endpoint median PFS, pazopanib 8.4 months versus 9.5 months with sunitinib (95% CI 0.90–
1.22). Median OS, pazopanib 28.4 months versus sunitinib 29.3 months (HR 0.91; p = 0.28), 
was not significantly different, whereas the ORR was significantly higher in the pazopanib 
group (31% versus 25%; p = 0.03). Fatigue, hand-foot syndrome and thrombocytopenia 
were more frequent with sunitinib, while increased levels of alanine aminotransferase were 
higher with pazopanib; quality of life analysis favoured pazopanib [Motzer et al. 2013]. 
A second, smaller phase III trial (PISCES) supported the results of the COMPARZ trial. In 
total, 169 patients with mRCC were randomized to receive either first-line pazopanib for 10 
weeks, followed by sunitinib for 10 weeks or the reverse sequence. The primary endpoint 
was patient preference at week 22. Significantly more patients preferred pazopanib (70%) 
to sunitinib (22%; p < 0.001). The main reasons for pazopanib preference were less fatigue 
and better overall quality of life [Escudier et al. 2014b]. Preliminary data from a 
retrospective analysis with 3606 patients with mRCC in a population-based setting, who 
received first-line treatment with sunitinib or pazopanib were recently presented. There 
was no difference in terms of ORR (sunitinib 30.3% versus pazopanib 25.7%; p = 0.09), 
median PFS (sunitinib 7.2 months versus pazopanib 6.8 months; p = 0.49) or median OS 
(sunitinib 20.1 months versus pazopanib 23.6 months; p = 0.19) between the two drugs 
[Morales et al. 2016]. 
Other first-line treatment recommendations in clear cell mRCC are bevacizumab plus IFN-α, 
sorafenib or axitinib. There are no phase III trials which compared these agents against 
sunitinib. The recommendation as a first-line treatment for bevacizumab plus IFN-α (NCCN 
guidelines 02.2016 category 1) is based on the results of two phase III trials (AVOREN and 
CALGB90206), which compared bevacizumab plus IFN-α versus IFN-α alone. Bevacizumab 
plus IFN-α improved the median PFS [Escudier et al. 2010; Rini et al. 2010b] but due to side 
effects and the inconvenience of IFN-α administration, this regimen is not widely used. 
Sorafenib is recommended as an option for first-line treatment for clear cell mRCC (category 
2A in NCCN guidelines 02.2016, option in ESMO guidelines version 2014) [NCCN Panel 
Members, 2016a; Escudier et al. 2014a]. The evidence for sorafenib use at first-line is less 
strong as it has shown to prolong PFS compared with placebo after (mainly cytokine based) 
first-line treatment of patients with mRCC in a phase III trial (TARGET) [Escudier et al. 
2007a], but failed to demonstrated superiority in a phase II trial against IFN-α in untreated 
patients [Escudier et al. 2009]. Axitinib, a second generation TKI has been investigated in a 
phase III trial against sorafenib in the first-line setting but failed to show an improvement 
[Hutson et al. 2013]. 
An overview of the first-line trials between sunitinib, pazopanib, bevacizumab plus IFN-α 
and sorafenib is set out in Table 7. 
 
Sunitinib and non-clear cell renal cancer 
Non-clear cell RCC represents a histologically and genetically diverse group of cancers that 
arise from the kidney [Bitting et al. 2011; Shuch et al. 2015; Armstrong et al. 2016]. In 
contrast to clear cell RCC, the evidence for sunitinib treatment in non-clear cell RCC is less 
strong, as most of the phase III trials in RCC have restricted the enrolment to patients whose 
tumours are of clear cell subtype. Data are available from several retrospective and 
prospective phase II trials, which have focused on non-clear cell RCC histology, as well as 
from a subgroup analyses of the large EAP [Choueiri et al. 2008; Yildiz et al. 2014; Paglino et 
al. 2012; Shi et al. 2015; Molina et al. 2012a; Tannir et al. 2012; Ravaud et al. 2015; Lee et al. 
2012; Gore et al. 2015]. 
Two randomized prospective phase II trials compared everolimus and sunitinib as first-line 
treatment in non-clear cell RCC. The first trial (ESPN), published an interim analysis in 2015. 
The results showed no benefit for everolimus in terms of median PFS (sunitinib 6.1 months, 
everolimus 4.1 months) and median OS (sunitinib 16.2 months, everolimus 14.9 months) 
and both agents demonstrated only modest efficacy [Tannir et al. 2015]. The second trial 
(ASPEN) showed a significant increase in the median PFS with sunitinib (8.3 months) versus 
everolimus (5.6 months; HR 1.41; p = 0.16, prespecified level of statistical significance 0.20) 
while the median OS was not different between the two groups. However, there was a 
difference in the treatment effect based on histological subtypes and prognostic risk groups 
[chromophobe subtype (median PFS 11.4 months versus 5.5 months)] and MSKCC poor-risk 
group (median PFS 6.1 months versus 4.0 months) favoured everolimus in exploratory 
nonpowered subgroups [Armstrong et al. 2016]. These differences demonstrate that non-
clear cell RCC is not a homogeneous disease group and one should be aware of this in the 
interpretation of trial data. 
Given these data, sunitinib is still recommended as an option for first-line treatment in non-
clear cell RCC in current guidelines, especially for patients with good MSKCC risk scores 
[NCCN Panel Members, 2016a; Escudier et al. 2014a]. But as the overall efficacy in non-clear 
cell RCC remains poor with the current treatment options, the need for individual 
morphological subtype and genotype analysis and developing of new agents according to 
morphological subtype and genomic signalling remains urgent and patients should be 
offered entering into clinical trials if possible [Tannir et al. 2015; Armstrong et al. 2016]. 
Tables 8 and 9 give an overview of the different trials with sunitinib in advanced non-clear 
cell RCC. 
 
Is there a role for sunitinib as adjuvant treatment? 
To date, the standard approach for patients with localized or locally-advanced RCC who 
have undergone nephrectomy is surveillance [NCCN Panel Members, 2016a; Escudier et al. 
2014a]. Various studies did not show a benefit for immune treatment (cytokines or 
autologous tumour cell vaccines) versus observation in the adjuvant setting of RCC 
[Pizzocaro et al. 2001; Messing et al. 2003; Clark et al. 2003; Passalacqua et al. 2007; 
Atzpodien et al. 2001; Jocham et al. 2004; Wood et al. 2008]. 
Several trials are investigating the adjuvant use of targeted treatment in RCC. Data from 
randomized trials testing sorafenib (SORCE trial), axitinib (ATLAS trial), pazopanib (PROTECT 
trial) and everolimus (EVEREST S0931) versus placebo are not published yet (by the end of 
June 2016; Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to 
Remove Kidney Cancer (SORCE) [ClinicalTrials.gov identifier: NCT00492258]; Adjuvant 
Axitinib Therapy of RCC in High Risk Patients (ATLAS) [ClinicalTrials.gov identifier: 
[NCT01599754]; A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized 
Renal Cell Carcinoma (RCC; PROTECT) [ClinicalTrials.gov identifier: NCT01235962]; 
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (EVEREST 
S0931) [ClinicalTrials.gov identifier: NCT01120249]. 
Sunitinib was tested in two randomized trials (ASSURE and S-TRAC). The ASSURE trial was a 
double-blind placebo-controlled randomized phase III trial that compared 54 weeks of 
sunitinib or sorafenib with placebo in the adjuvant setting of 1943 patients with resected 
RCC at high risk for recurrence. Patients were randomly assigned (1:1:1) to receive sunitinib, 
sorafenib or placebo. The primary endpoint of disease free survival (DFS) was not 
significantly different between each experimental arm and the placebo arm [median DFS for 
sunitinib 5.8 years (HR for sunitinib versus placebo 1.02; 97.5% CI 0.85–1.23; p = 0.8038), for 
sorafenib 6.1 years (HR for sorafenib versus placebo 0.97; 97.5% CI 0.80–1.17; p = 0.7184) 
and for placebo 6.6 years]. Substantial treatment discontinuation due to toxicity occurred in 
the sunitinib and sorafenib arm [Haas et al. 2016]. 
S-TRAC is a phase III randomized trial, which tested sunitinib for 1 year versus placebo in the 
adjuvant setting of more than 670 patients with resected RCC at high risk of recurrence (A 
Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment 
Of Patients At High Risk Of Recurrent RCC (S-TRAC) [ClinicalTrials.gov identifier: 
NCT00375674]. A press release by the drug company Pfizer on 8 July 2016 announced, that 
the trial met its primary endpoint DFS, while the adverse events were consistent with the 
known safety profile of sunitinib [Pfizer Press Release, 2016]. At the time of writing this 
review, no other information is in the public domain, but results are expected to be 
presented at the ESMO 2016 Congress in Copenhagen in October 2016. It has to be waited 
until the full results are published to see, if sunitinib has a potential use in the adjuvant 
setting of patients with resected RCC at high risk of recurrence. 
 
Immunotherapy and future perspectives 
Immunotherapy with IL-2 has a curative potential in a small subset of mRCC patients, but its 
role has been replaced by targeted agents (TKI and VEGF inhibition) due to higher rates of 
clinical benefit and better toxicity profiles [Gore et al. 2010]. 
However, the new generation of immunotherapies with immune checkpoint inhibitors (e.g. 
anti-PD1 or anti PDL-1 agents) have shown very promising results in various tumour types 
including RCC. For example, nivolumab, the PD1 checkpoint inhibitor has been compared 
with everolimus at second-line following sunitinib failure (CheckMate 025 trial). Nivolumab 
was superior to everolimus in terms of median OS (25.0 versus 19.6 months; HR 0.73; p = 
0.002), ORR (25% versus 5%; p < 0.001) and tolerability (frequency of grade 3 or 4 adverse 
events 19% versus 37%), respectively [Motzer et al. 2015]. Nivolumab is likely to become a 
standard of care in the second-line treatment of mRCC following these results. 
Sunitinib was initially investigated as a novel first-line treatment to replace interferon. Now 
it is frequently the comparator arm in first-line trials against novel agents. Preliminary 
results from a phase I study that investigates the anti-PD1 antibody nivolumab in 
combination with sunitinib, pazopanib or ipilimumab (Checkmate016), have been 
mentioned above [Amin et al. 2014; Nivolumab (BMS-936558; MDX-1106) in Combination 
with Sunitinib, Pazopanib, or Ipilimumab in Subjects with Metastatic Renal Cell Carcinoma 
(RCC; CheckMate 016) [ClinicalTrials.gov identifier: NCT01472081]. Another phase I and II 
trial compares varlilumab (anti-CD27 antibody) and sunitinib and is currently (by the end of 
June 2016) recruiting (A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients with 
Metastatic Clear Cell Renal Cell Carcinoma [ClinicalTrials.gov identifier: NCT02386111]. 
Several phase III trials are comparing immunotherapy in combination against the standard 
first-line sunitinib treatment. A randomized phase III trial (CheckMate 214) of nivolumab 
plus ipilimumab versus sunitinib in first-line treatment of mRCC is ongoing, but not 
recruiting patients to date (by the end of June 2016; Nivolumab Combined with Ipilimumab 
Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 
(CheckMate 214) [ClinicalTrials.gov identifier: NCT02231749]. Another phase III trial 
(JAVELIN Renal 101) is comparing avelumab (anti-PDL-1 antibody) with axitinib versus 
sunitinib and currently (by the end of June 2016) recruiting patients (A Study of Avelumab 
with Axitinib Versus Sunitinib In Advanced RCC (JAVELIN Renal 101) [ClinicalTrials.gov 
identifier: NCT02684006]. A further phase III trial investigates atezolizumab (anti-PDL-1 
antibody) in combination with bevacizumab versus sunitinib and is currently (by the end of 
June 2016) recruiting patients (A Study of Atezolizumab in Combination with Bevacizumab 
Versus Sunitinib in Participants with Untreated Advanced Renal Cell Carcinoma 
[ClinicalTrials.gov identifier: NCT02420821]. 
Sunitinib has been a standard first-line treatment in mRCC for the last decade. The main 
question in the coming years will be where sunitinib will have its position with regard to the 
new immune-checkpoint inhibitors. Will sunitinib lose its role as a preferred first-line option 
to the new-checkpoint-inhibitors, will it keep its role as standard single agent treatment or 
will there be a usage in combination with immune-checkpoint inhibitors? 
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